Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland, which highlighted the role of immune cells assigned to protect the body from the disease in actually promoting the spread of cancer - a process called metastasis.
The research published in Nature identified a subset of circulating tumour cell clusters using ANGLE's technology that was demonstrated to be associated with greatly increased metastatic ability.
Understanding the role of the patient’s own immune system in aiding cancer spread opens the potential for the development of new therapies that impede the process.
"Research into CTC clusters using the Parsortix system has the potential to change the way that cancer is treated,” said ANGLE founder and chief executive Andrew Newland.
“The publication of the University of Basel's research in Nature on CTC-neutrophil clusters, following the previous publication in Cell, is a tremendous achievement for Basel, one of ANGLE's leading customers.
“We are delighted that the harvesting of CTC clusters, using the Parsortix system, is a key element in the drive to block the process of cancer metastasis that is responsible for over 90% of deaths from cancer."